CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation
The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...
Drug
Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...
Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...
Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...
LaNova Medicines Gets NMPA Approval for LM-305 Clinical Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd has announced that it has received approval from...
Everest Medicines’ Nefecon NDA Accepted for IgA Nephropathy in China
China-based biotech Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...
Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...
Yabao Receives FDA Clearance for Generic Nexavar
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...
Hengrui’s Pyrotinib Granted Priority Review for HER2-Positive Breast Cancer
The Center for Drug Evaluation (CDE) website has announced that China-based Hengrui Pharmaceuticals’ (SHA: 600276)...
AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...
Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that China-based Akeso Biopharma (HKG: 9926) has...
HutchMed Announces Initial Results from FRUTIGA Phase III Study
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initial results from...
Henlius Biotech’s BRAF V600E Inhibitor HLX208 Approved for Clinical Study in China
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
FDA Approves Phase Ib Study for Jiangsu Yahong’s APL1401 in Ulcerative Colitis
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...
CDE Prioritizes Review for Jiedi Pharma’s Mitotane and Other Key Drugs
The Center for Drug Evaluation (CDE) website indicates that market filings for several key drugs,...
CanSino Biologics’ Inhalable COVID-19 Vaccine Authorized in Morocco
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
Luye Pharma’s Biosimilar LY06006/BA6101 Approved for Osteoporosis Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Lundbeck’s Eptinezumab Launches in Boao Lecheng for Migraine Treatment
Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone,...
RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis
The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...